Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Jian-Chang Lin · SciRah

Researcher profile · Semantic Scholar

Jian-Chang Lin

Share profile

Jian-Chang Lin — researcher profile on SciRah

h-index: 22
Works: 80
Citations: 2,834

Most-cited papers

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +22 more
2016New England Journal of Medicine988 citations Open access
Semantic Scholar
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Cai-Cun Zhou, S. Ramalingam, T. Kim, Sang-We Kim +14 more
2021JAMA Oncology224 citations Open access
Semantic Scholar
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review
S. Kolluri, Jian-Chang Lin, Rachael Liu, Yan-Wei Zhang +1 more
2022AAPS Journal222 citations Open access
Semantic Scholar
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
Gregory Riely, J. Neal, D. Camidge, A. Spira +18 more
2021Cancer Discovery167 citations Open access
Semantic Scholar
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
H. Avet-Loiseau, N. Bahlis, W. Chng, T. Masszi +19 more
2017Blood112 citations
Semantic Scholar
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +21 more
201575 citations
Semantic Scholar
Principal stratum strategy: Potential role in drug development
B. Bornkamp, K. Rufibach, Jian-Chang Lin, Yi Liu +5 more
2020Pharmaceutical statistics65 citations Open access
Semantic Scholar
Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Jian-Chang Lin, V. Bunn
2017Contemporary Clinical Trials62 citations
Semantic Scholar
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji K. Kumar, P. Moreau, P. Hari, M. Mateos +16 more
2017British Journal of Haematology56 citations Open access
Semantic Scholar
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
M. Mateos, T. Masszi, N. Grząśko, M. Hansson +14 more
2017Haematologica50 citations Open access
Semantic Scholar
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
S. Ou, H. Lin, Jin-Liern Hong, Yu Yin +5 more
2023JTO Clinical and Research Reports42 citations Open access
Semantic Scholar
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C. Smith, T. Kalebic, J. Infante, L. Siu +13 more
2015Investigational new drugs42 citations Open access
Semantic Scholar
A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +11 more
201142 citations
Semantic Scholar
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
E. Fedyk, Lin Zhao, A. Koch, G. Smithson +6 more
2020British Journal of Clinical Pharmacology40 citations Open access
Semantic Scholar
Bayesian semiparametric meta‐analytic‐predictive prior for historical control borrowing in clinical trials
B. Hupf, V. Bunn, Jian-Chang Lin, Cheng Dong
2021Statistics in Medicine37 citations
Semantic Scholar
Innovative trial designs and analyses for vaccine clinical development
Mengya Liu, Qing Li, Jian-Chang Lin, Yun-Zhi Lin +1 more
2020Contemporary Clinical Trials34 citations Open access
Semantic Scholar
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
P. Jänne, Bin-Chao Wang, B. Cho, Jun Zhao +16 more
2025Journal of Clinical Oncology32 citations Open access
Semantic Scholar
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
S. Ou, H. Lin, Jin-Liern Hong, Yu Yin +5 more
202130 citations
Semantic Scholar
Practical considerations of utilizing propensity score methods in clinical development utilizing real-world and historical data.
Qing Li, Jian-Chang Lin, Andy Chi, Sheryl M. Davies
2020Contemporary Clinical Trials25 citations
Semantic Scholar
Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata
Mo Li, Rachael Liu, Jian-Chang Lin, V. Bunn +1 more
2020Journal of Biopharmaceutical Statistics25 citations
Semantic Scholar
A General Overview of Adaptive Randomization Design for Clinical Trials
Jian-Chang Lin, Li-An Lin, S. Sankoh
201624 citations Open access
Semantic Scholar
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
A. Krishnan, K. Patel, P. Hari, S. Jagannath +7 more
2019Blood23 citations Open access
Semantic Scholar
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
S. Ramalingam, Cai-Cun Zhou, T. Kim, Sang-We Kim +13 more
202122 citations
Semantic Scholar
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy
Pin Li, Rachael Liu, Jian-Chang Lin, Yuan Ji
2020Journal of Biopharmaceutical Statistics21 citations
Semantic Scholar
Adaptive design implementation in confirmatory trials: Methods, practical considerations and case studies.
Qing Li, Jian-Chang Lin, Yun-Zhi Lin
2020Contemporary Clinical Trials20 citations
Semantic Scholar
Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
L. Horn, H. Lin, S. Padda, C. Aggarwal +7 more
202019 citations
Semantic Scholar
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).
D. Siegel, A. Krishnan, S. Lonial, G. Chatta +16 more
200619 citations
Semantic Scholar
Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation
Ajeeta B. Dash, Jacob Zhang, Lei Shen, Bin Li +7 more
2020European Journal of Haematology18 citations Open access
Semantic Scholar
Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect
Qing Li, Jian-Chang Lin, Mengya Liu, Liwen Wu +1 more
2021Statistics in Biopharmaceutical Research17 citations
Semantic Scholar
Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
Steven Zhang, Shu-min Jin, C. Griffin, Zhongling Feng +3 more
2021Clinical pharmacology in drug development16 citations Open access
Semantic Scholar
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Rachael Liu, Jian-Chang Lin, Pin Li
2020Contemporary Clinical Trials16 citations
Semantic Scholar
Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
Steven Zhang, Shu-min Jin, C. Griffin, Zhongling Feng +5 more
2021Clinical pharmacology in drug development15 citations Open access
Semantic Scholar
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
N. Gupta, Anna Largajolli, H. Witjes, P. Diderichsen +4 more
2022Clinical pharmacology and therapy14 citations Open access
Semantic Scholar
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
L. Garderet, J. Laubach, A. Stoppa, P. Hari +10 more
2018Leukemia14 citations Open access
Semantic Scholar
Semiparametric Bayesian survival analysis using models with log-linear median
Jian-Chang Lin, D. Sinha, S. Lipsitz, A. Polpo
2012Biometrics14 citations Open access
Semantic Scholar
Practical Recommendations for Regional Consistency Evaluation in Multi-Regional Clinical Trials with Different Endpoints
Zhao-Yang Teng, Jian-Chang Lin, Bin Zhang
201812 citations
Semantic Scholar
Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
Jian-Chang Lin, V. Bunn, Rachael Liu
2019Statistics in Biopharmaceutical Research10 citations
Semantic Scholar
Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints
A. Sinha, L. Moye, L. Piller, Jose-Miguel Yamal +3 more
2019Statistics in Medicine10 citations
Semantic Scholar
Flexible seamless 2-in-1 design with sample size adaptation
Run-Jia Li, Liwen Wu, Rachael Liu, Jian-Chang Lin
2022Journal of Biopharmaceutical Statistics9 citations Open access
Semantic Scholar
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Jie Yang, Cai-Cun Zhou, P. Jänne, S. Ramalingam +17 more
2022Expert Review of Anticancer Therapy9 citations Open access
Semantic Scholar
Incorporating Surrogate Information for Adaptive Subgroup Enrichment Design with Sample Size Re-Estimation
Liwen Wu, Qing Li, Mengya Liu, Jian-Chang Lin
2021Statistics in Biopharmaceutical Research9 citations Open access
Semantic Scholar
Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
P. Richardson, H. Avet-Loiseau, A. Palumbo, L. Viterbo +16 more
20169 citations
Semantic Scholar
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
S. Ou, H. Lin, Jin-Liern Hong, Yu Yin +6 more
2023Lung Cancer8 citations Open access
Semantic Scholar
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses
J. Pan, V. Bunn, B. Hupf, Jian-Chang Lin
2022Journal of Biopharmaceutical Statistics8 citations
Semantic Scholar
c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma
Alessandra Di Bacco, N. Bahlis, N. Munshi, H. Avet-Loiseau +20 more
2020European Journal of Haematology8 citations Open access
Semantic Scholar
Adaptive Randomization for Master Protocols in Precision Medicine
Jian-Chang Lin, Li-An Lin, V. Bunn, Rachael Liu
2019Contemporary Biostatistics with Biopharmaceutical Applications8 citations
Semantic Scholar
A Bayesian Response-adaptive Covariate-adjusted Randomization Designfor Clinical Trials
Jian-Chang Lin, Li-An Lin, S. Sankoh
20168 citations
Semantic Scholar
Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol
Ziji Yu, Liwen Wu, V. Bunn, Qing Li +1 more
2023Therapeutic Innovation and Regulatory Science7 citations
Semantic Scholar
OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
A. Spira, S. Ramalingam, J. Neal, Z. Piotrowska +16 more
2021Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Alessandra Di Bacco, N. Bahlis, N. Munshi, H. Avet-Loiseau +20 more
20167 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Berg×13
Invite
D. Berg — researcher profile on SciRah
V. Bunn×12
Invite
V. Bunn — researcher profile on SciRah
P. Moreau×10
Invite
P. Moreau — researcher profile on SciRah
Alessandra Di Bacco×9
Invite
Alessandra Di Bacco — researcher profile on SciRah

×9

Invite

P. Richardson — researcher profile on SciRah

Invite

T. Masszi — researcher profile on SciRah

Invite

N. Bahlis — researcher profile on SciRah

Invite

L. Pour — researcher profile on SciRah

H. Van de Velde×7

Invite

H. Van de Velde — researcher profile on SciRah

Danny Nguyen×7

Invite

Danny Nguyen — researcher profile on SciRah

Invite

M. Mehta — researcher profile on SciRah

Invite

P. Ganly — researcher profile on SciRah